A5101886867- Schizophrenia research and treatment
- Treatment of Major Depression
- Bipolar Disorder and Treatment
- Pharmaceutical Practices and Patient Outcomes
- Dementia and Cognitive Impairment Research
- Mental Health and Psychiatry
- Nail Diseases and Treatments
- Psychosomatic Disorders and Their Treatments
- Clinical practice guidelines implementation
- Chemotherapy-related skin toxicity
- Health Systems, Economic Evaluations, Quality of Life
- Cytokine Signaling Pathways and Interactions
- Family Caregiving in Mental Illness
- Cancer Treatment and Pharmacology
- Reproductive tract infections research
- Chronic Disease Management Strategies
- HER2/EGFR in Cancer Research
- Intensive Care Unit Cognitive Disorders
- Estrogen and related hormone effects
- Cervical Cancer and HPV Research
St. Vincent's University Hospital
2024
Vanderbilt University Medical Center
2024
St. James's Hospital
2021-2023
Bord na Móna (Ireland)
2021
Eli Lilly (United Kingdom)
2004-2005
Health Economics and Outcomes Research (United Kingdom)
2004
Cancer immunotherapy has transformed the TNBC tx landscape but new combinations are needed to further improve survival outcomes. Atezo (PD-L1 inhibitor) + nab-paclitaxel (nab-P) is approved for first-line (1L) of PD-L1+, inoperable LA/mTNBC. SG (Trop-2-directed antibody–drug conjugate) 2L+ mTNBC. We present 18-week IA atezo arm in MORPHEUS-panBC (NCT03424005). Eligible pts with no prior systemic LA/mTNBC were randomised receive control (atezo 840 mg IV on Day [D] 1 & 15 nab-P 100 mg/m2 D1, 8...
Objective: To present the 6‐month outcomes associated with antipsychotic treatment of patients participating in Schizophrenia Outpatient Health Outcomes (SOHO) study. Method: SOHO is a 3‐year, prospective, observational study health 10 European countries. The included over 000 out‐patients who were initiating or changing their medication. Results: Clinical Global Impression (CGI)‐severity and quality life (QOL) scores improved all cohorts. There was higher response CGI‐overall symptoms...
Objective: The European Schizophrenia Out‐patient Health Outcomes study is an observational investigating treatment in schizophrenia. We report treatment‐emergent adverse events during the first 6 months of treatment. Method: rate extrapyramidal symptoms (EPS), anticholinergic use, weight gain and sexual related dysfunctions were assessed 8400 out‐patients. Results: Patients typical antipsychotics risperidone experienced significantly more EPS use than patients clozapine, olanzapine,...
The present study aimed to compare health outcomes and tolerability according antipsychotic medication (olanzapine, risperidone or an oral typical antipsychotic) after 6 months of treatment in a group 919 schizophrenic patients who had never previously been treated with antipsychotics. Demographic clinical predictors outcome were also identified. Data extracted from the Schizophrenia Outpatient Health Outcomes (SOHO) study, prospective, observational schizophrenia 10 European countries....
Mild cognitive impairment (MCI) may represent an intermediate, prodromal phase of dementia. Although persons with MCI (PwMCI) are able to function independently, they often experience reduced ability carry out their usual activities. This can result in social, emotional and functional challenges.To explore the understanding psychosocial impact receiving a diagnosis on patients carers.A cross-sectional cohort study was conducted at St James's Hospital Memory Clinic involving who attended...
Background Medications with anticholinergic activity are widely prescribed for a variety of medical, surgical, and psychiatric illnesses. There is strong evidence that the cumulative properties such medications (i.e., burden) contributes to significant longer-term adverse effects, including dementia, impaired mobility, increased mortality. Despite this, burden often not given due consideration when cliniciansprescribe or review in routine clinical practice. This particularrelevance services...